Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Travere Therapeutics, Inc. - Common Stock
(NQ:
TVTX
)
64.03
+8.01 (+14.30%)
Streaming Delayed Price
Updated: 11:28 AM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics, Inc. - Common Stock
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Where Travere Therapeutics Stands With Analysts
↗
July 26, 2022
Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings within the last quarter:
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
June 17, 2022
Gainers Travere Therapeutics (NASDAQ:TVTX) stock increased by 16.5% to $28.87 during Friday's after-market session. The market value of their outstanding shares is at $1.8 billion.
Via
Benzinga
Analyst Ratings for Travere Therapeutics
↗
May 17, 2022
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings:
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Travere Therapeutics: Here's What You Need To Know
↗
May 17, 2022
HC Wainwright & Co. has decided to maintain its Buy rating of Travere Therapeutics (NASDAQ:TVTX) and raise its price target from $45.00 to $46.00. Shares of Travere Therapeutics are trading up 8.5%...
Via
Benzinga
Travere Therapeutics Pops After Snagging Priority Review For A New Kidney Drug
↗
May 16, 2022
The FDA will review Travere's drug by mid-November for a kidney disease.
Via
Investor's Business Daily
FDA Accepts Travere Therapeutics' NDA for Sparsentan with Priority Review
↗
May 16, 2022
The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ: TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of...
Via
Benzinga
Earnings Scheduled For October 28, 2021
↗
October 28, 2021
Companies Reporting Before The Bell • LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million. •...
Via
Benzinga
Here's Why Travere Therapeutics Shares Are Rising Today
↗
May 16, 2022
Travere Therapeutics Inc (NASDAQ: TVTX) shares are trading higher by 7.66% at $23.88 after the company received a priority review from the FDA for its treatment of IgA Nephropathy...
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
↗
May 06, 2022
Gainers Kiromic BioPharma (NASDAQ:KRBP) stock increased by 12.6% to $0.58 during Friday's after-market session. The market value of their outstanding shares is at $8.9 million.
Via
Benzinga
Earnings Outlook For Retrophin
↗
May 04, 2022
Retrophin (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that Retrophin will...
Via
Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
↗
May 02, 2022
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks...
Via
Benzinga
The Daily Biotech Pulse: Ampio Falls On Knee Osteoarthritis Trial Update, AstraZeneca's COVID-19 Antibody Data, CureVac-GSK's Bivalent COVID-19 Vaccine Data
↗
April 21, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
↗
April 10, 2022
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Via
Benzinga
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
↗
March 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
↗
March 31, 2022
Upgrades
Via
Benzinga
Travere Therapeutics: Q4 Earnings Insights
↗
February 24, 2022
Travere Therapeutics (NASDAQ:TVTX) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:01 PM. Here's what investors need to know about the announcement....
Via
Benzinga
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
↗
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
↗
February 28, 2022
Upgrades According to DA Davidson, the prior rating for Envestnet Inc (NYSE:ENV) was changed from Neutral to Buy. In the fourth quarter, Envestnet showed an EPS of $0.50, compared...
Via
Benzinga
Travere Therapeutics's Earnings: A Preview
↗
February 23, 2022
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-02-24. Here's what investors need to know before the announcement....
Via
Benzinga
Biotech Travere Therapeutics Stock Earns Relative Strength Rating Upgrade
↗
February 14, 2022
Travere shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.
Via
Investor's Business Daily
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
↗
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Travere Posts Topline Data For Pegtibatinase In patients With Rare Metabolic Disorder
↗
December 15, 2021
Travere Therapeutics Inc (NASDAQ: TVTX) reported topline results from the ongoing Phase 1/2 COMPOSE Study of pegtibatinase for classical homocystinuria (HCU)....
Via
Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
↗
October 28, 2021
Gainers Bellerophon Therapeutics (NASDAQ:
Via
Benzinga
The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug
↗
October 28, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...
Via
Benzinga
PleasrDAO Aint Nothing To F*** With: Wu Tang Clan Album Once Owned By Shkreli Has Been Purchased
↗
October 22, 2021
From the slums of Shaolin, Wu-Tang Clan strikes again. An exclusive album made by the legendary hip-hop group is back in the news ...
Via
Benzinga
The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More
↗
October 24, 2021
Biotech stocks posted gains for the second week running, supported by multiple catalysts that included a good start to the big pharma reporting season and broader market strength...
Via
Benzinga
8 Health Care Stocks With Unusual Options Alerts In Today's Session
↗
September 16, 2021
This unusual options alert can help traders track potentially big trading opportunities. Traders often look for circumstances when the market estimation of an option diverges away...
Via
Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
↗
September 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand
September 16, 2021
From
Vifor Pharma Group
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
September 15, 2021
Gainers Larimar Therapeutics (NASDAQ:
Via
Benzinga
< Previous
1
2
...
9
10
11
12
13
14
15
16
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
